Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Front Med (Lausanne) ; 10: 1180799, 2023.
Article in English | MEDLINE | ID: mdl-37387784

ABSTRACT

Background: Staging of melanoma and follow up after melanoma diagnosis aims at predicting risk and detecting progression or recurrence at early stage, respectively in order to timely start and/or change treatment. Tumor thickness according to Breslow, status of the sentinel node and value of the lactate dehydrogenase (LDH) are well-established prognostic markers for metastatic risk, but reliable biomarkers identifying early recurrence or candidates who may benefit best from medical treatment are still warranted. Liquid biopsy has emerged to be a suitable method for identifying biomarkers for early cancer diagnosis, prognosis, therapeutic response prediction, and patient follow-up. Liquid biopsy is a blood-based non-invasive procedure that allows analyzing circulating analytes, including extracellular vesicles. Methods: In this study we have explored the use of 7 miRNAs, namely hsa-miR-149-3p, hsa-miR-150-5p, hsa-miR-21-5p, hsa-miR-200c-3p, hsa-miR-134-5p, hsa-miR-144-3p and hsa-miR-221-3p in plasma exosomes to discriminate melanoma patients from controls without melanoma in a cohort of 92 individuals. Results and discussion: Our results showed that three out seven miRNAs, namely hsa-miR-200c-3p, hsa-miR-144-3p and hsa-miR-221-3p were differentially expressed in plasma-derived exosomes from melanoma patients and controls. Furthermore, the expression of the three miRNAs may be a promising ancillary tool as a melanoma biomarker, even for discriminating between nevi and melanoma.

3.
Dermatol Ther (Heidelb) ; 10(5): 1089-1098, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32749663

ABSTRACT

INTRODUCTION: Few data on possible local factors that can influence the achievement of response in nonsegmental vitiligo (NSV) treated with narrowband ultraviolet B (Nb-UVB) phototherapy are available. Our objective is to evaluate possible correlations between therapeutic outcomes and dermoscopic and local (lesional) clinical findings of vitiligous lesions undergoing Nb-UVB phototherapy to find positive and/or negative response predictor factors to such treatment. METHODS: For each target patch, we calculated the extension area using a computer-aided method and assessed dermoscopic and local (lesional) clinical findings at baseline. After 30 phototherapy sessions (twice weekly), surface area of the lesions was reevaluated to assess clinical improvement, correlating the therapeutic outcome with initial clinical and dermoscopic features. RESULTS: A total of 70 lesions were finally included in the study. At the end of therapy, 18 patches (25.7%) achieved improvement, and the presence of perifollicular pigmentation on baseline dermoscopic examination was found to be associated with a 12-fold higher probability of having a positive therapeutic outcome. Similarly, face localization was also correlated with clinical amelioration, with a sevenfold higher probability for improvement. No association (p > 0.05) between therapeutic outcomes (either good or poor) and other dermoscopic or local clinical variables (including leukotrichia) was observed. CONCLUSIONS: Therapeutic response of vitiligo to Nb-UVB phototherapy may be positively affected by local features of the lesions, i.e., face localization and presence of perifollicular pigmentation on baseline dermoscopic examination, which might be considered as positive response predictor factors to optimize treatment of vitiligo.

4.
G Ital Dermatol Venereol ; 155(4): 452-458, 2020 Aug.
Article in English | MEDLINE | ID: mdl-29582618

ABSTRACT

BACKGROUND: Cyclosporine A (CyA) is a drug for moderate-to-severe psoriasis. Recently, a generic formulation has been approved as bioequivalent to the branded one. The guidelines for the bioequivalence for critical-dose drugs with a narrow therapeutic range, such as CyA, are questionable. Therefore, it is important to assess the clinical outcome and the pharmacokinetics of different formulations in various patient groups. The current literature lacks of this information in dermatology. The primary objective of this prospective study is to investigate the clinical equivalence (in terms of maintenance of clinical effect) between the generic formulation of CyA and its branded one in patients with psoriasis. A secondary objective is to analyze their trough (C0) and peak levels (C2). METHODS: Twenty patients with stable psoriasis under treatment with the branded CyA were monitored in terms of clinical efficacy (psoriasis area severity index, PASI), safety (laboratory values), and their pharmacokinetics utilizing trough (C0) and peak plasma concentration (C2). The same patients were subsequently shifted to the generic formulation for comparison. RESULTS: In our sample the efficacy of the two formulations was equal in most cases (P=0.863). A non-significant difference between the C0 and C2 of the branded CyA compared to the generic one emerged (respectively P=0.738 and P=0.695). CONCLUSIONS: The branded and the generic formulations of CyA seem to be not only bioequivalent, but also comparable in terms of clinical efficacy in patients with psoriasis. However, larger samples are required to confirm these findings.


Subject(s)
Cyclosporine/administration & dosage , Dermatologic Agents/administration & dosage , Drugs, Generic/administration & dosage , Psoriasis/drug therapy , Adult , Cross-Over Studies , Cyclosporine/pharmacokinetics , Dermatologic Agents/pharmacokinetics , Drugs, Generic/pharmacokinetics , Female , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/pharmacokinetics , Male , Middle Aged , Prospective Studies , Psoriasis/pathology , Severity of Illness Index , Therapeutic Equivalency , Treatment Outcome
6.
Environ Technol ; 39(15): 1886-1897, 2018 Aug.
Article in English | MEDLINE | ID: mdl-28612648

ABSTRACT

This paper describes the development of a method for recovery of phosphorous from one of the waste waters at an Akzo Nobel chemical plant in Ale close to Göteborg. It was found that it is possible to transform the phosphorous in the waste water to a saleable product, i.e. a slowly dissolving fertilizer. The developed process includes oxidation of phosphite to phosphate with hydrogen peroxide and heat. The phosphate is then precipitated as crystalline struvite (ammonium magnesium phosphate) by the addition of magnesium chloride. The environmental impacts of the new method were compared with those of the current method using life cycle assessment. It was found that the methodology developed in this project was an improvement compared with the current practice regarding element resource depletion and eutrophication. However, the effect on global warming would be greater with the new method. There could however be several ways to decrease the global warming effect. Since most of the carbon dioxide emissions come from the production of magnesium chloride from carbonates, changing to utilization of a magnesium chloride from desalination of seawater or from recycling of PVC would decrease the carbon footprint significantly.


Subject(s)
Phosphorus/chemistry , Wastewater , Carbon Footprint , Chemical Precipitation , Industrial Waste , Magnesium Compounds , Phosphates , Struvite , Waste Disposal, Fluid , Water
7.
Case Rep Womens Health ; 9: 4-6, 2016 Jan.
Article in English | MEDLINE | ID: mdl-29594011

ABSTRACT

Ulcus vulvae acutum is a rare clinical condition characterized by the presence of multiple acute painful genital ulcers of non-venereal origin associated with systemic symptoms in young women. The aetiopathogenesis of the disease is not fully understood, although recent reports have associated it with the Epstein-Barr virus. Diagnosis is difficult and generally made by exclusion after venereal diseases, and autoimmune, inflammatory, traumatic, and neoplastic causes. We describe a case of adolescent female with an episode of ulcus vulvae acutum associated with infectious mononucleosis. The diagnosis was supported by the clinical symptoms, elevated circulating levels of liver enzymes, positive EBV serology, cervical and inguinal lymphadenomegaly, and hepatosplenomegaly. The patient presented a history of aphthous stomatitis. Negative Pathergy test and the absence of any other related symptoms allowed us to exclude the Behçhet syndrome. Lesions healed with no sequelae or recurrences.

8.
Article in English | MEDLINE | ID: mdl-26697732

ABSTRACT

Parry-Romberg syndrome is an acquired slowly progressive disease characterized by an atrophy mostly involving half of the face. The pathogenesis of this disfiguring condition is still controversial. The relationship between Parry-Romberg syndrome and Lyme disease needs to be considered in depth. A 16-year-old woman from Albania presented with linear depressions of the right side of the face, clinically compatible with Parry-Romberg syndrome. She had a positive history of Lyme disease. Borrelia infection was confirmed by the positivity of PCR and the presence of IgM antibodies. The patient received intravenous penicillin and metronidazole for 14 days. After treatment and during a 2-year follow-up, the clinical disease progression was halted and the serological and microbiological tests for Borrelia burgdorferi sensu lato were negative. We cannot exclude a coincidence, however, of the bacteriological and serological evidence. Moreover, the interruption of the disease progression after the antibiotic therapy is difficult to ignore without claiming that this association is at least suggestive.


Subject(s)
Borrelia burgdorferi/isolation & purification , Facial Hemiatrophy/microbiology , Lyme Disease/complications , Adolescent , Albania , Anti-Infective Agents/therapeutic use , Borrelia burgdorferi/immunology , Disease Progression , Face , Facial Hemiatrophy/diagnosis , Facial Hemiatrophy/drug therapy , Female , Humans , Lyme Disease/blood , Lyme Disease/drug therapy , Metronidazole/therapeutic use , Penicillins/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...